Search

Your search keyword '"Houot, R"' showing total 482 results
Start Over Author "Houot, R"
482 results on '"Houot, R"'

7. Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.

Author

Carras, S., primary, Torroja, A., additional, Emadali, A., additional, Daguindau, N., additional, Tempescul, A., additional, Macro, M., additional, Moreau, A., additional, Tchernonog, E., additional, Houot, R., additional, Schmitt, A., additional, Dartigeas, C., additional, Dupuis, J., additional, Jardin, F., additional, Banos, A., additional, Corm, S., additional, Barbieux, S., additional, Zerazhi, H., additional, Arkam, Y., additional, Fouillet, L., additional, Fontan, J., additional, Vilque, J., additional, Moles, M., additional, Sarkozy, C., additional, Morineau, N., additional, Joly, B., additional, Voillat, L., additional, Alexis, M., additional, Fornecker, L. M., additional, Garidi, R., additional, Amorim, S., additional, Bouabdallah, K., additional, Dorvaux, V., additional, Chabrot, C., additional, Feugier, P., additional, Damaj, G., additional, Fleury, J., additional, Delwail, V., additional, Ysebaert, L., additional, Burroni, B., additional, Callanan, M., additional, Legouill, S., additional, and Gressin, R., additional

Published
2023
Full Text
View/download PDF

8. Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSA

Author

Marouf, A., primary, Chaubard, S., additional, Michot, J., additional, Liévin, R., additional, Rossignol, J., additional, Golfier, C., additional, Allangba, O., additional, Philippe, L., additional, Tessoulin, B., additional, Chauchet, A., additional, Deau, B., additional, Oberic, L., additional, Vargaftig, J., additional, Moignet, A., additional, Clavert, A., additional, Dulery, R., additional, Brisou, G., additional, Tardy, S., additional, Fataccioli, V., additional, Houot, R., additional, Casasnovas, R., additional, Thieblemont, C., additional, Ghesquières, H., additional, Carras, S., additional, Le Gouill, S., additional, Cartron, G., additional, Marabelle, A., additional, Tournilhac, O., additional, Damaj, G., additional, Gaulard, P., additional, De Leval, L., additional, Lemonnier, F., additional, Bachy, E., additional, Hermine, O., additional, Couronné, L., additional, and Jaccard, A., additional

Published
2023
Full Text
View/download PDF

9. CAR‐T CELLS RADICALLY MODIFY THE MANAGEMENT OF RELAPSED/REFRACTORY PRIMARY CEREBRAL LYMPHOMAS. REAL LIFE RESULTS OF THE FRENCH LOC NETWORK

Author

Choquet, S., primary, Soussain, C., additional, Waultier‐Rascalou, A., additional, Xuan, K. Hoang, additional, Guffroy, B., additional, Ahle, G., additional, Barrie, M., additional, Galicier, L., additional, Diblasi, R., additional, Ursu, R., additional, Houot, R., additional, Alcantara, M., additional, Salanouba, C., additional, Willems, L., additional, Gauthier, N., additional, Quoc, S. Nguyen, additional, Metz, C., additional, Uzunov, M., additional, Morel, V., additional, Weil, D. Roos, additional, Souchet, L., additional, Legarff‐Tavernier, M., additional, and Houillier, C., additional

Published
2023
Full Text
View/download PDF

10. Allogeneic transplantation in T‐cell lymphoma: Lessons from the AATT study

Author

Tournilhac, O., primary, Altmann, B., additional, Friedrichs, B., additional, Bouabdallah, K., additional, Cartron, G., additional, Nickelsen, M., additional, Wulf, G., additional, Leclerc, M., additional, Vilatte, A., additional, Turlure, P., additional, Sanhès, L., additional, Houot, R., additional, Roussel, M., additional, de Leval, L., additional, Rosenwald, A., additional, Gaulard, P., additional, Dreger, P., additional, Glass, B., additional, Latière, C., additional, Damaj, G., additional, Lenz, G., additional, Reimer, P., additional, Banos, A., additional, Bilger, K., additional, Durot, E., additional, Sibon, D., additional, Wagner, E., additional, Nguyen, S., additional, Trümper, L., additional, Ziepert, M., additional, and Schmitz, N., additional

Published
2023
Full Text
View/download PDF

11. RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY

Author

Thieblemont, C., primary, Lamy, T., additional, Tani, M., additional, Krzisch, D., additional, Reda, G., additional, Tedeschi, A., additional, Usai, S. V., additional, Guarini, A., additional, Bijou, F., additional, Stathis, A., additional, Anastasia, A., additional, Devizzi, L., additional, Luminari, S., additional, Arcaini, L., additional, Casasnovas, O., additional, Gressin, R., additional, André, M., additional, Houot, R., additional, Bonomini, L., additional, Zucca, E., additional, and Conconi, A., additional

Published
2023
Full Text
View/download PDF

12. COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA

Author

Hutchings, M., primary, Dickinson, M., additional, Carlo‐Stella, C., additional, Morschhauser, F., additional, Bosch, F., additional, Gritti, G., additional, Townsend, W., additional, Bartlett, N. L., additional, Cartron, G., additional, Ghesquieres, H., additional, Houot, R., additional, Walter, H., additional, Offner, F., additional, Christiansen, A., additional, Dimier, N., additional, Jamois, C., additional, Harrop, E., additional, Herter, S., additional, Hölzlwimmer, G., additional, Keelara, A., additional, Korfi, K., additional, Luong, J., additional, Mueller, C., additional, Mycroft, S., additional, Whayman, M., additional, Prieto, I., additional, Rukina, D., additional, and Lechner, K., additional

Published
2023
Full Text
View/download PDF

13. Remote monitoring of CAR T‐cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA program

Author

Colin, F., primary, Bellec, A., additional, Le Bars, L., additional, Granger, M., additional, De Guibert, S., additional, Manson, G., additional, Lhomme, F., additional, Marchand, T., additional, Mear, J., additional, Barbe, M. Escoffre, additional, Decaux, O., additional, Lamy de la Chapelle, T., additional, Houot, R., additional, and Autrel, A. Moignet, additional

Published
2023
Full Text
View/download PDF

14. 3‐Year outcomes of adults with relapsed or refractory B‐cell acute lymphoblastic leukemia treated with brexu‐cel in ZUMA‐3 by age, prior therapies, and subsequent transplant

Author

Shah, B. D., primary, Cassaday, R. D., additional, Park, J. H., additional, Houot, R., additional, Oluwole, O. O., additional, Logan, A. C., additional, Boissel, N., additional, Leguay, T., additional, Bishop, M. R., additional, Topp, M. S., additional, O’Dwyer, K. M., additional, Baer, M. R., additional, Schiller, G. J., additional, Abedi, M., additional, Minnema, M. C., additional, Stiff, P., additional, Zhou, L., additional, Hadjivassileva, T., additional, Khalid, R. Damico, additional, and Ghobadi, A. Armin, additional

Published
2023
Full Text
View/download PDF

15. AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY

Author

Houot, R., primary, Bachy, E., additional, Cartron, G., additional, Gros, F., additional, Morschhauser, F., additional, Oberic, L., additional, Gastinne, T., additional, Feugier, P., additional, Dulery, R., additional, Thieblemont, C., additional, Joris, M., additional, Jardin, F., additional, Choquet, S., additional, Casasnovas, O., additional, Brisou, G., additional, Cheminant, M., additional, Bay, J., additional, Gutierrez, F. Llamas, additional, Menard, C., additional, Tarte, K., additional, Delfau, M., additional, Itti, E., additional, Bailly, C., additional, Al Tabaa, Y., additional, Laurent, C., additional, and Lemonnier, F., additional

Published
2023
Full Text
View/download PDF

16. VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.

Author

Sarkozy, C., primary, Thieblemont, C., additional, Oberic, L., additional, Moreau, A., additional, Bouabdallah, K., additional, Damaj, G., additional, Gastine, T., additional, Ribrag, V., additional, Casasnovas, O., additional, Haioun, C., additional, Houot, R., additional, Jardin, F., additional, Van Den Neste, E., additional, Cheminant, M., additional, Morschhauser, F., additional, Callana, M., additional, Ghesquieres, H., additional, Gressin, R., additional, Hermine, O., additional, and Le Gouill, S., additional

Published
2023
Full Text
View/download PDF

17. Baseline [18F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphoma.

Author

Marchal, E., Palard-Novello, X., Lhomme, F., Meyer, M. E., Manson, G., Devillers, A., Marolleau, J. P., Houot, R., and Girard, A.

Subjects
B cells, B cell lymphoma, T cells, OVERALL survival, CYTOKINE release syndrome, BODY surface area
Abstract

Purpose: Chimeric antigen receptor (CAR) T cells have established themselves as an effective treatment for refractory or relapsed large B cell lymphoma (LBCL). Recently, the sDmax, which corresponds to the distance separating the two farthest lesions standardized by the patient's body surface area, has appeared as a prognostic factor in LBCL. This study aimed to identify [18F]FDG-PET biomarkers associated with prognosis and predictive of adverse events in patients treated with CAR T cells. Methods: Patients were retrospectively included from two different university hospitals. They were being treated with CAR T cells for LBCL and underwent [18F]FDG-PET just before CAR T cell infusion. Lesions were segmented semi-automatically with a threshold of 41% of the maximal uptake. In addition to clinico-biological features, sDmax, total metabolic tumor volume (TMTV), SUVmax, and uptake intensity of healthy lymphoid organs and liver were collected. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The occurrence of adverse events, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), was reported. Results: Fifty-six patients were included. The median follow-up was 9.7 months. Multivariate analysis showed that TMTV (cut-off of 36 mL) was an independent prognostic factor for PFS (p < 0.001) and that sDmax (cut-off of 0.15 m−1) was an independent prognostic factor for OS (p = 0.008). Concerning the occurrence of adverse events, a C-reactive protein level > 35 mg/L (p = 0.006) and a liver SUVmean > 2.5 (p = 0.027) before CAR T cells were associated with grade 2 to 4 CRS and a spleen SUVmean > 1.9 with grade 2 to 4 ICANS. Conclusion: TMTV and sDmax had independent prognostic values, respectively, on PFS and OS. Regarding adverse events, the mean liver and spleen uptakes were associated with the occurrence of grade 2 to 4 CRS and ICANS, respectively. Integrating these biomarkers into the clinical workflow could be useful for early adaptation of patients management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Author

Rejeski, K, Subklewe, M, Aljurf, M, Bachy, E, Balduzzi, A, Barba, P, Bruno, B, Benjamin, R, Carrabba, M, Chabannon, C, Ciceri, F, Corradini, P, Delgado, J, Di Blasi, R, Greco, R, Houot, R, Iacoboni, G, Jaeger, U, Kersten, M, Mielke, S, Nagler, A, Onida, F, Peric, Z, Roddie, C, Ruggeri, A, Sanchez-Guijo, F, Sánchez-Ortega, I, Schneidawind, D, Schubert, M, Snowden, J, Thieblemont, C, Topp, M, Zinzani, P, Gribben, J, Bonini, C, Sureda Balari, A, Yakoub-Agha, I, Rejeski, Kai, Subklewe, Marion, Aljurf, Mahmoud, Bachy, Emmanuel, Balduzzi, Adriana Cristina, Barba, Pere, Bruno, Benedetto, Benjamin, Reuben, Carrabba, Matteo Giovanni, Chabannon, Christian, Ciceri, Fabio, Corradini, Paolo, Delgado, Julio, Di Blasi, Roberta, Greco, Raffaella, Houot, Roch, Iacoboni, Gloria, Jaeger, Ulrich, Kersten, Marie José, Mielke, Stephan, Nagler, Arnon, Onida, Francesco, Peric, Zinaida, Roddie, Claire, Ruggeri, Annalisa, Sanchez-Guijo, Fermin M, Sánchez-Ortega, Isabel, Schneidawind, Dominik, Schubert, Maria-Luisa, Snowden, John, Thieblemont, Catherine, Topp, Max S, Zinzani, Pierluigi Luigi, Gribben, John G, Bonini, Chiara, Sureda Balari, Anna, Yakoub-Agha, Ibrahim, Rejeski, K, Subklewe, M, Aljurf, M, Bachy, E, Balduzzi, A, Barba, P, Bruno, B, Benjamin, R, Carrabba, M, Chabannon, C, Ciceri, F, Corradini, P, Delgado, J, Di Blasi, R, Greco, R, Houot, R, Iacoboni, G, Jaeger, U, Kersten, M, Mielke, S, Nagler, A, Onida, F, Peric, Z, Roddie, C, Ruggeri, A, Sanchez-Guijo, F, Sánchez-Ortega, I, Schneidawind, D, Schubert, M, Snowden, J, Thieblemont, C, Topp, M, Zinzani, P, Gribben, J, Bonini, C, Sureda Balari, A, Yakoub-Agha, I, Rejeski, Kai, Subklewe, Marion, Aljurf, Mahmoud, Bachy, Emmanuel, Balduzzi, Adriana Cristina, Barba, Pere, Bruno, Benedetto, Benjamin, Reuben, Carrabba, Matteo Giovanni, Chabannon, Christian, Ciceri, Fabio, Corradini, Paolo, Delgado, Julio, Di Blasi, Roberta, Greco, Raffaella, Houot, Roch, Iacoboni, Gloria, Jaeger, Ulrich, Kersten, Marie José, Mielke, Stephan, Nagler, Arnon, Onida, Francesco, Peric, Zinaida, Roddie, Claire, Ruggeri, Annalisa, Sanchez-Guijo, Fermin M, Sánchez-Ortega, Isabel, Schneidawind, Dominik, Schubert, Maria-Luisa, Snowden, John, Thieblemont, Catherine, Topp, Max S, Zinzani, Pierluigi Luigi, Gribben, John G, Bonini, Chiara, Sureda Balari, Anna, and Yakoub-Agha, Ibrahim

Abstract

Hematological toxicity is the most common adverse event after chimeric antigen receptor (CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for severe infectious complications. In a recent worldwide survey, we demonstrated that there remains considerable heterogeneity in regard to current practice patterns. Here, we sought to build consensus on the grading and management of immune effector cell–associated hematotoxicity (ICAHT) after CAR T-cell therapy. For this purpose, a joint effort between the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA) involved an international panel of 36 CAR T-cell experts who met in a series of virtual conferences, culminating in a 2-day meeting in Lille, France. On the basis of these deliberations, best practice recommendations were developed. For the grading of ICAHT, a classification system based on depth and duration of neutropenia was developed for early (day 0-30) and late (after day +30) cytopenia. Detailed recommendations on risk factors, available preinfusion scoring systems (eg, CAR-HEMATOTOX score), and diagnostic workup are provided. A further section focuses on identifying hemophagocytosis in the context of severe hematotoxicity. Finally, we review current evidence and provide consensus recommendations for the management of ICAHT, including growth factor support, anti-infectious prophylaxis, transfusions, autologous hematopoietic stem cell boost, and allogeneic hematopoietic cell transplantation. In conclusion, we propose ICAHT as a novel toxicity category after immune effector cell therapy, provide a framework for its grading, review literature on risk factors, and outline expert recommendations for the diagnostic workup and short- and long-term management.

Published
2023

21. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study

Author

Schorb, E, Fox, C P, Fritsch, K, Isbell, L, Neubauer, A, Tzalavras, A, Witherall, R, Choquet, S, Kuittinen, O, De-Silva, D, Cwynarski, K, Houillier, C, Hoang-Xuan, K, Touitou, V, Cassoux, N, Marolleau, J-P, Tamburini, J, Houot, R, Delwail, V, Illerhaus, G, Soussain, C, and Kasenda, B

Published
2017
Full Text
View/download PDF

24. S210: CAR T-CELLS ASSOCIATED ACUTE TOXICITY IN B-CELL NON-HODGKIN LYMPHOMA: REAL-WORLD STUDY FROM THE DESCAR-T REGISTRY

Author

SESQUES, P., primary, DI BLASI, R., additional, LE GOUILL, S., additional, CARTRON, G., additional, MANSON, G., additional, BEAUVAIS, D., additional, LE BRAS, F., additional, GROS, F. X., additional, CHOQUET, S., additional, BORIES, P., additional, RUBIO, M. T., additional, CASASNOVAS, R. O., additional, BOUNAIX, L., additional, MOHTY, M., additional, JORIS, M., additional, ABRAHAM, J., additional, CASTILLA LLORENTE, C., additional, LOSCHI, M., additional, CARRAS, S., additional, CHAUCHET, A., additional, DRIEU LA ROCHELLE, L., additional, ZERBIT, J., additional, HERMINE, O., additional, GUIDEZ, S., additional, GASTINNE, T., additional, TUDESQ, J. J., additional, FOGARTY, P., additional, BROUSSAIS, F., additional, MORSCHHAUSER, F., additional, HOUOT, R., additional, THIEBLEMONT, C., additional, and BACHY, E., additional

Published
2022
Full Text
View/download PDF

25. P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2

Author

Wang, M. L., primary, Munoz, J., additional, Goy, A., additional, Locke, F. L., additional, Jacobson, C. A., additional, Hill, B. T., additional, Timmerman, J. M., additional, Holmes, H., additional, Flinn, I. W., additional, Miklos, D. B., additional, Pagel, J. M., additional, Kersten, M. J., additional, Houot, R., additional, Beitinjaneh, A., additional, Peng, W., additional, Fang, X., additional, Shen, R. R., additional, Siddiqi, R., additional, Kloos, I., additional, and Reagan, P. M., additional

Published
2022
Full Text
View/download PDF

26. P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY.

Author

Cartron, G., primary, Bachy, E., additional, Tilly, H., additional, Daguindau, N., additional, Pica, G.-M., additional, Bijou, F., additional, Mounier, C., additional, Clavert, A. M., additional, Damaj, G. L., additional, Slama, B., additional, Casasnovas, O., additional, Houot, R., additional, Bouabdallah, K., additional, Sibon, D., additional, Fitoussi, O., additional, Morineau, N., additional, Herbaux, C., additional, Gastinne, T., additional, Fornecker, L.-M., additional, Haioun, C., additional, Launay, V., additional, Araujo, C., additional, Benbrahim, O., additional, Sanhes, L., additional, Gressin, R., additional, Gonzalez, H., additional, Morschhauser, F., additional, Xerri, L., additional, Tarte, K., additional, and Pranger, D., additional

Published
2022
Full Text
View/download PDF

27. S260: A MATCHED COMPARISON OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL CAR T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE LYSA STUDY FROM THE FRENCH DESCAR-T REGISTRY

Author

Bachy, E., primary, Le Gouill, S., additional, Sesques, P., additional, Di Blasi, R., additional, Guillaume, M., additional, Cartron, G., additional, Beauvais, D., additional, Roulin, L., additional, Gros, F. X., additional, Rubio, M. T., additional, Bories, P., additional, Bay, J. O., additional, Castilla Llorente, C., additional, Choquet, S., additional, Casasnovas, R.-O., additional, Mothy, M., additional, Guidez, S., additional, Joris, M., additional, Loschi, M., additional, Carras, S., additional, Abraham, J., additional, Chauchet, A., additional, Drieu La Rochelle, L., additional, Zerbit, J., additional, Hermine, O., additional, Gastinne, T., additional, Tudesq, J. J., additional, Gat, E., additional, Broussais, F., additional, Thieblemont, C., additional, Houot, R., additional, and Morschhauser, F., additional

Published
2022
Full Text
View/download PDF

28. P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3

Author

Shah, B. D., primary, Cassaday, R. D., additional, Park, J. H., additional, Houot, R., additional, Oluwole, O. O., additional, Logan, A. C., additional, Boissel, N., additional, Leguay, T., additional, Bishop, M. R., additional, Topp, M. S., additional, Tzachanis, D., additional, O’Dwyer, K. M., additional, Arellano, M. L., additional, Lin, Y., additional, Baer, M. R., additional, Schiller, G. J., additional, Subklewe, M., additional, Abedi, M., additional, Minnema, M. C., additional, Wierda, W. G., additional, DeAngelo, D. J., additional, Stiff, P., additional, Jeyakumar, D., additional, Dong, J., additional, Adhikary, S., additional, Zhou, L., additional, Schuberth, P. C., additional, Kharabi Masouleh, B., additional, and Ghobadi, A., additional

Published
2022
Full Text
View/download PDF

31. Premiers résultats de l’étude PRAISE (Patient-Reported AutoImmunity SEcondary to cancer immunotherapy) : étude de cohorte prospective multicentrique pour le suivi des manifestations auto-immunes survenant sous immunothérapie anticancéreuse

Author

Sebbag, E., primary, Barthelemy, P., additional, Sedmak, N., additional, Hamamouche, N., additional, Servy, H., additional, Desjeux, G., additional, Cloarec, N., additional, Najem, A., additional, Monnet, I., additional, Porneuf, M., additional, Meunier, J., additional, Darut-Jouve, A., additional, San, T., additional, Chauvenet, L., additional, Falkowski, S., additional, Rizzo, C., additional, Cannelas, A., additional, Cadranel, J., additional, Debieuvre, D., additional, Weiss, L., additional, Chouaid, C., additional, Girard, N., additional, Aparicio, T., additional, Houot, R., additional, Nancey, S., additional, Arnold, C., additional, Sauleau, E., additional, and Gottenberg, J.E., additional

Published
2021
Full Text
View/download PDF

34. Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy

Author

Nair, R., Drillet, G., Lhomme, F., Le Bras, A., Michel, L., Rossi, J., Sherman, M., Xue, A., Kerber, A., Jittapiromsak, N., Chi, L., Tummala, S., Neelapu, S.S., Houot, R., The University of Texas M.D. Anderson Cancer Center [Houston], Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Kite (Gilead), Chulalongkorn University [Bangkok], Jonchère, Laurent, and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV] Life Sciences [q-bio], Receptors, Chimeric Antigen, [SDV]Life Sciences [q-bio], Humans, Case Reports, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Quadriplegia, Immunotherapy, Adoptive, ComputingMilieux_MISCELLANEOUS
Abstract

International audience; [No abstract available]

Published
2020

35. Allogreffe dans les lymphomes T cutanés avancés (CUTALLO) : une étude prospective contrôlée multicentrique, appariée par score de propension

Author

De Masson, A., Beylot-Barry, M., Ram-Wolff, C., Méar, J.B., Dalle, S., D’incan, M., Oro, S., Orvain, C., Abraham, J., Dereure, O., Charbonnier, A., Cornillon, J., Longvert, C., Barete, S., Boulinguez, S., Wierzbicka-Hainaut, E., Aubin, F., Rubio, M.T., Bernard, M., Schmidt-Tanguy, A., Houot, R., Pham-Ledard, A., Michonneau, D., Brice, P., Labussière-Wallet, H., Bouaziz, J.D., Grange, F., Moins-Teisserenc, H., Jondeau, K., Michel, L., Mourah, S., Battistella, M., Daguindau, E., Loschi, M., Picard, A., Franck, N., Maillard, N., Huynh, A., Nguyen, S., Marcais, A., Chaby, G., Ceballos, P., Le Corre, Y., Maury, S., Bay, J.O., Adamski, H., Bachy, E., Forcade, E., Socié, G., Bagot, M., Chevret, S., and Peffault De Latour, R.

Published
2023
Full Text
View/download PDF

36. EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B‐CELL LYMPHOMA : RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY.

Author

Delfau‐Larue, M., Viailly, P., Cartron, G., Morschhauser, F., Gros, F., Gastinne, T., Oberic, L., Bachy, E., Dulery, R., Feugier, P., Menard, C., Quelen, C., Pangault, C., Portugues, C., Gomes, L., Itti, E., Bailly, C., Lemonnier, F., Laurent, C., and Houot, R.

Subjects
CIRCULATING tumor DNA, T cells, LYMPHOMAS
Abstract

EARLY CTDNA CLEARANCE AFTER CAR T-CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B-CELL LYMPHOMA: RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY B Introduction: b CAR T-cells have significantly improved the outcome of patients with relapsed or refractory ( I R i / I R i ) large B-cell lymphoma (LBCL). The aim of our study was to monitor ctDNA before and after CAR T-cell infusion and correlate the results with clinical outcome in the ALYCANTE trial. [Extracted from the article]

Published
2023
Full Text
View/download PDF

37. FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES

Author

Gouill, S., primary, Bachy, E., additional, Blasi, R., additional, Cartron, G., additional, Beauvais, D., additional, Bras, F., additional, Gros, François‐X., additional, Choquet, S., additional, Bories, P., additional, Rubio, Marie‐Thérès., additional, Casasnovas, René‐O., additional, Bounaix, L., additional, Mohty, M., additional, Joris, M., additional, Gastinne, T., additional, Sesques, P., additional, Tudesq, J. J., additional, Morschhauser, F., additional, Gat, E., additional, Broussais, F., additional, Thieblemont, C., additional, and Houot, R., additional

Published
2021
Full Text
View/download PDF

39. PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP

Author

Al Tabaa, Y., primary, Casasnovas, O., additional, Baillet, C., additional, Bachy, E., additional, Virelizier, E. Nicolas, additional, Schiano de Colella, J. M., additional, Bailly, C., additional, Kanoun, S., additional, Guidez, S., additional, Gyan, E., additional, Gressin, R., additional, Morineau, N., additional, Ysebaert, L., additional, Le Gouill, S., additional, Tilly, H., additional, Houot, R., additional, Morschhauser, F., additional, Cartron, G., additional, and Herbaux, C., additional

Published
2021
Full Text
View/download PDF

40. ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA

Author

Cartron, G., primary, Bachy, E., additional, Guidez, S., additional, Gyan, E., additional, Gressin, R., additional, Morineau, N., additional, Sibon, D., additional, Casasnovas, O., additional, Le Gouill, S., additional, Tilly, H., additional, Ysebaert, L., additional, Schiano de Colella, J. M., additional, Feugier, P., additional, Virelizier, E. Nicolas, additional, Haioun, C., additional, Damaj, G., additional, Tarte, K., additional, Laurent, C., additional, Houot, R., additional, Thieblemont, C., additional, Morschhauser, F., additional, and Herbaux, C., additional

Published
2021
Full Text
View/download PDF

41. PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38)

Author

Pirosa, M. C., primary, Orsucci, L., additional, Feugier, P., additional, Tani, M., additional, Ghesquieres, Hervé, additional, Musuraca, G., additional, Baldini, L., additional, Merli, F., additional, Renzis, B., additional, Gyan, E., additional, Gini, G., additional, Marino, D., additional, Gressin, R., additional, Morschhauser, F., additional, Palombi, F., additional, Cavallo, F., additional, Conconi, A., additional, Gouill, S., additional, Tilly, Hervé, additional, Zanni, M., additional, Cabras, M. G., additional, Capochiani, E., additional, Califano, C., additional, Molinari, A. L., additional, Pulsoni, A., additional, Angrilli, F., additional, Cartron, G., additional, Casasnovas, O., additional, Devizzi, L., additional, Haioun, C., additional, Houot, R., additional, Liberati, A. M., additional, Occhini, U., additional, Merli, M., additional, Pietrantuono, G., additional, Re, F., additional, Spina, M., additional, Esposito, F., additional, Bertoni, F., additional, Rossi, D., additional, Ielmini, N., additional, Luminari, S., additional, Cavalli, F., additional, Zucca, E., additional, Stathis, A., additional, and Thieblemont, C., additional

Published
2021
Full Text
View/download PDF

42. ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA

Author

Herbaux, C., primary, Schiano de Colella, J. M., additional, Thieblemont, C., additional, Guidez, S., additional, Ysebaert, L., additional, Tilly, H., additional, Gouill, S., additional, Houot, R., additional, Bachy, E., additional, Laurent, C., additional, Damaj, G., additional, Feugier, P., additional, Morineau, N., additional, Tarte, K., additional, Morschhauser, F., additional, and Cartron, G., additional

Published
2021
Full Text
View/download PDF

43. OUTCOMES AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDY

Author

Camus, V., primary, Rossi, C., additional, Sesques, P., additional, Lequesne, J., additional, Tonnelet, D., additional, Haioun, C., additional, Durot, E., additional, Willaume, A., additional, Gauthier, M., additional, Moles‐Moreau, Marie‐P., additional, Antier, C., additional, Lazarovici, J., additional, Monjanel, H., additional, Bernard, S., additional, Tardy, M., additional, Besson, C., additional, Lebras, L., additional, Choquet, S., additional, Le Du, K., additional, Bonnet, C., additional, Bailly, S., additional, Damaj, G.‐L., additional, Laribi, K., additional, Maisonneuve, H., additional, Houot, R., additional, Chauchet, A., additional, Jardin, F., additional, Traverse‐Glehen, A., additional, Decazes, P., additional, Becker, S., additional, Berriolo‐Riedinger, A., additional, and Tilly, H., additional

Published
2021
Full Text
View/download PDF

44. The EHA research Roadmap: Immune-based therapies for hematological malignancies

Author

Einsele, H., Briones, J., Ciceri, F., Cadenas, I. G., Falkenburg, F., Bolanos, N., Heemskerk, H. M. M., Houot, R., Hudecek, M., Locatelli, Franco, Morgan, K., Morris, E. C., O'Dwyer, M., Sierra, J. G., van den Brink, M., van de Loosdrecht, A. A., Locatelli F. (ORCID:0000-0002-7976-3654), Einsele, H., Briones, J., Ciceri, F., Cadenas, I. G., Falkenburg, F., Bolanos, N., Heemskerk, H. M. M., Houot, R., Hudecek, M., Locatelli, Franco, Morgan, K., Morris, E. C., O'Dwyer, M., Sierra, J. G., van den Brink, M., van de Loosdrecht, A. A., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1–2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European Hematology Research. the 11 EHA Research Roadmap sections include normal hematopoiesis; malignant lymphoid diseases; malignant myeloid diseases; anemias and related diseases; platelet disorders; blood coagulation and hemostatic disorders; transfusion medicine; infections in hematology; hematopoietic stem cell transplantation; CAR-T and Other cell-based immune therapies; and gene therapy.

Published
2021

47. Immune-based therapies for hematological malignancies: an update by the EHA SWG on immunotherapy of hematological malignancies

Author

Einsele, H., Briones, J., Ciceri, F., Garcia-Cadenas, I., Falkenburg, F., Bolanos, N., Heemskerk, H.M.M., Houot, R., Hudecek, M., Locatelli, F., Morgan, K., Morris, C.E., O'Dwyer, M., Gil, J.S., Brink, M. van den, Loosdrecht, A.A. van de, Einsele, Hermann, Briones, Javier, Ciceri, Fabio, García-Cadenas, Irene, Falkenburg, Fred, Bolaños, Natacha, Heemskerk, H. M. Mirjam, Houot, Roch, Hudecek, Michael, Locatelli, Franco, Morgan, Kate, Morris, C. Emma, O’Dwyer, Michael, Gil, Jordi Sierra, van den Brink, Marcel, van de Loosdrecht, Arjan A., HAL UR1, Admin, University Hospital of Würzburg, Hospital de la Santa Creu i Sant Pau, IRCCS San Raffaele Scientific Institute [Milan, Italie], Leiden University Medical Center (LUMC), Departamento de Inteligencia Artificial [UPM, Spain] (DIA), Universidad Politécnica de Madrid (UPM), Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Dana-Farber Cancer Institute [Boston], IRCCS Ospedale Pediatrico Bambino Gesù [Roma], Royal Free Hospital [London, UK], National University of Ireland [Galway] (NUI Galway), Memorial Sloane Kettering Cancer Center [New York], VU University Medical Center [Amsterdam], Universiteit Leiden, Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV] Life Sciences [q-bio], Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, lcsh:RC633-647.5, [SDV]Life Sciences [q-bio], Perspective, HSCT, lcsh:Diseases of the blood and blood-forming organs, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

48. Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx

Author

Thurner, L., Poeschel, V, Haioun, C., Houot, R., Gaulard, P., Molina, T., Rosenwald, A., Andre, M., Hoffmann, J., Dreyling, M., Casasnovas, O., Maisonneuve, H., Tilly, H., Illmer, T., Mayer, S., Kirchen, H., La Rosee, P., Loeffler, M., Ziepert, M., Altmann, B, Held, G., Jonchère, Laurent, Saarland University [Saarbrücken], CHI Créteil, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Julius-Maximilians-Universität Würzburg (JMU), CHU UCL Namur, Philipps Universität Marburg = Philipps University of Marburg, University-Hospital Munich-Großhadern [München], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Universität Regensburg (UR), Universität Leipzig, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Philipps Universität Marburg, Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon, and Universität Leipzig [Leipzig]

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results